Latest Research in Myeloma and Plasma Cell Disorders

Top Research Topics in Myeloma and Plasma Cell Disorders

• Multiple Myeloma Research and Treatments — 68 papers
• CAR-T cell therapy research — 15 papers
• Chronic Lymphocytic Leukemia Research — 7 papers
• Mast cells and histamine — 3 papers
• Cutaneous lymphoproliferative disorders research — 3 papers
• Extracellular vesicles in disease — 2 papers
• Inflammatory Biomarkers in Disease Prognosis — 2 papers
• Dermatologic Treatments and Research — 2 papers
• Statistical Methods in Clinical Trials — 2 papers
• Immune cells in cancer — 2 papers

Highest-Cited Papers

1. Hyperdiploid multiple myeloma: A heterogeneous entity requiring refined risk stratification—Insights from chromosome count and cytogenetic abnormalities
2. The EF1α promoter of cilta-cel drives a highly effective GZMK+ transcriptional program
3. Incidentally detected vertebral fractures and risk of myeloma: a prospective cohort study of 9059 CT-scanned Danish general population individuals
4. Metagenomic Deep Sequencing Identifies Gene Mutations Associated with Chemotherapeutic Resistance in Vitreoretinal Lymphoma
5. Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy
6. The Clinical and Molecular Characteristics of Systemic Mastocytosis with Associated Non-Mast Cell Myeloid Neoplasm
7. Diagnostic and prognostic value of bone metabolism biomarkers in newly diagnosed plasma cell myeloma
8. Mapping the scientific research on mesenchymal stromal cells and multiple myeloma: a bibliometric analysis
9. Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis
10. Are all risk factors created equal in multiple myeloma?
11. Salvage Autologous Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma: Long-Term Efficacy and Safety Outcomes from a Single-Center Real-World Cohort
12. Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma – the BELI(E)VE trial
13. Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies
14. The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma
15. T-cell dynamics, CD8/NK ratio and tumor survival hallmarks determine response to T-cell bispecific forimtamig in myeloma
16. Schwann Cell Expression Pattern in Human Melanomas: In Silico and Immunohistochemical Analyses
17. Toxicity‐Related Treatment Cessation in Newly Diagnosed Multiple Myeloma—Risk Factors and Survival: An Analysis From the APAC and ANZ Myeloma and Related Diseases Registry
18. Cutaneous Toxicities of Anti‐ GPRC 5 D Bispecific Antibodies for Multiple Myeloma: Retrospective Study
19. Identification of broadly tumour-reactive γδ TCRs from multiple myeloma
20. Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma

Sub-Regions

• Lymphoma Diagnosis and Treatment — 96 papers
• Multiple Myeloma Research and Treatments — 71 papers
• CAR-T cell therapy research — 34 papers
• Cutaneous Melanoma Detection and Management — 34 papers
• Polyomavirus and related diseases — 24 papers
• Chronic Lymphocytic Leukemia Research — 20 papers